PortalPublikationenRandomized trial on 14 versus 7 days of esomeprazole, moxifl...

Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection

Standard

Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. / Miehlke, Stephan; Krasz, Susanne; Schneider-Brachert, Wulf; Kuhlisch, Eberhard; Berning, Marco; Madisch, Ahmed; Laass, Martin W; Neumeyer, Michael; Jebens, Claus; Zekorn, Christian; Knoth, Holger; Vieth, Michael; Stolte, Manfred; Lehn, Norbert; Morgner, Andrea.

in: HELICOBACTER, Jahrgang 16, Nr. 6, 12.2011, S. 420-6.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Miehlke, S, Krasz, S, Schneider-Brachert, W, Kuhlisch, E, Berning, M, Madisch, A, Laass, MW, Neumeyer, M, Jebens, C, Zekorn, C, Knoth, H, Vieth, M, Stolte, M, Lehn, N & Morgner, A 2011, 'Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection', HELICOBACTER, Jg. 16, Nr. 6, S. 420-6. https://doi.org/10.1111/j.1523-5378.2011.00867.x

APA

Miehlke, S., Krasz, S., Schneider-Brachert, W., Kuhlisch, E., Berning, M., Madisch, A., Laass, M. W., Neumeyer, M., Jebens, C., Zekorn, C., Knoth, H., Vieth, M., Stolte, M., Lehn, N., & Morgner, A. (2011). Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. HELICOBACTER, 16(6), 420-6. https://doi.org/10.1111/j.1523-5378.2011.00867.x

Vancouver

Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. HELICOBACTER. 2011 Dez;16(6):420-6. https://doi.org/10.1111/j.1523-5378.2011.00867.x

Bibtex

@article{c7d7d851e1024cb391dbf1fe565710be,
title = "Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection",
abstract = "BACKGROUND: Triple therapy with a proton pump inhibitor, moxifloxacin, and amoxicillin has been proven effective in first-line treatment of Helicobacter pylori infection.AIM: To explore 1, the value of triple therapy with esomeprazole, moxifloxacin, and amoxicillin in second-line or rescue treatment of Caucasian patients and 2, the impact of treatment duration on eradication success.METHODS: H. pylori-infected patients with at least one previous treatment failure were randomized to oral esomeprazole 20 mg b.i.d., moxifloxacin 400 mg o.d., and amoxicillin 1000 mg b.i.d. for either 7 (EMA-7) or 14 days (EMA-14). Eradication was confirmed by 13C urea breath test. Antimicrobial susceptibility testing was performed in all patients at baseline and in patients who failed treatment.RESULTS: Eighty patients were randomized, and 60% had ≥ 2 previous treatment failures. Pretreatment resistance against clarithromycin and metronidazole was found in 70.5 and 61.5% of cases, respectively. The intention-to-treat eradication rate was significantly higher after EMA-14 compared with EMA-7 (95.0 vs 78.9%, p = .036). No independent risk factor for treatment failure could be identified. There were no serious adverse events. Five of the EMA-14 patients (12.5%) compared with none of the EMA-7 patients discontinued prematurely because of adverse events (p = .031). Post-treatment resistance against moxifloxacin was found in one of seven patients with isolated organisms (14.3%).CONCLUSION: Second-line/rescue H. pylori eradication therapy with esomeprazole, moxifloxacin, and amoxicillin is very effective and well tolerated. Fourteen days of treatment significantly increase the eradication rate but also the rate of adverse events.",
keywords = "Adult, Aged, Amoxicillin, Anti-Bacterial Agents, Anti-Ulcer Agents, Aza Compounds, Breath Tests, Drug Therapy, Combination, Esomeprazole, European Continental Ancestry Group, Female, Fluoroquinolones, Helicobacter Infections, Helicobacter pylori, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Quinolines, Salvage Therapy, Time Factors, Treatment Outcome, Urea, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",
author = "Stephan Miehlke and Susanne Krasz and Wulf Schneider-Brachert and Eberhard Kuhlisch and Marco Berning and Ahmed Madisch and Laass, {Martin W} and Michael Neumeyer and Claus Jebens and Christian Zekorn and Holger Knoth and Michael Vieth and Manfred Stolte and Norbert Lehn and Andrea Morgner",
note = "{\textcopyright} 2011 Blackwell Publishing Ltd.",
year = "2011",
month = dec,
doi = "10.1111/j.1523-5378.2011.00867.x",
language = "English",
volume = "16",
pages = "420--6",
journal = "HELICOBACTER",
issn = "1083-4389",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection

AU - Miehlke, Stephan

AU - Krasz, Susanne

AU - Schneider-Brachert, Wulf

AU - Kuhlisch, Eberhard

AU - Berning, Marco

AU - Madisch, Ahmed

AU - Laass, Martin W

AU - Neumeyer, Michael

AU - Jebens, Claus

AU - Zekorn, Christian

AU - Knoth, Holger

AU - Vieth, Michael

AU - Stolte, Manfred

AU - Lehn, Norbert

AU - Morgner, Andrea

N1 - © 2011 Blackwell Publishing Ltd.

PY - 2011/12

Y1 - 2011/12

N2 - BACKGROUND: Triple therapy with a proton pump inhibitor, moxifloxacin, and amoxicillin has been proven effective in first-line treatment of Helicobacter pylori infection.AIM: To explore 1, the value of triple therapy with esomeprazole, moxifloxacin, and amoxicillin in second-line or rescue treatment of Caucasian patients and 2, the impact of treatment duration on eradication success.METHODS: H. pylori-infected patients with at least one previous treatment failure were randomized to oral esomeprazole 20 mg b.i.d., moxifloxacin 400 mg o.d., and amoxicillin 1000 mg b.i.d. for either 7 (EMA-7) or 14 days (EMA-14). Eradication was confirmed by 13C urea breath test. Antimicrobial susceptibility testing was performed in all patients at baseline and in patients who failed treatment.RESULTS: Eighty patients were randomized, and 60% had ≥ 2 previous treatment failures. Pretreatment resistance against clarithromycin and metronidazole was found in 70.5 and 61.5% of cases, respectively. The intention-to-treat eradication rate was significantly higher after EMA-14 compared with EMA-7 (95.0 vs 78.9%, p = .036). No independent risk factor for treatment failure could be identified. There were no serious adverse events. Five of the EMA-14 patients (12.5%) compared with none of the EMA-7 patients discontinued prematurely because of adverse events (p = .031). Post-treatment resistance against moxifloxacin was found in one of seven patients with isolated organisms (14.3%).CONCLUSION: Second-line/rescue H. pylori eradication therapy with esomeprazole, moxifloxacin, and amoxicillin is very effective and well tolerated. Fourteen days of treatment significantly increase the eradication rate but also the rate of adverse events.

AB - BACKGROUND: Triple therapy with a proton pump inhibitor, moxifloxacin, and amoxicillin has been proven effective in first-line treatment of Helicobacter pylori infection.AIM: To explore 1, the value of triple therapy with esomeprazole, moxifloxacin, and amoxicillin in second-line or rescue treatment of Caucasian patients and 2, the impact of treatment duration on eradication success.METHODS: H. pylori-infected patients with at least one previous treatment failure were randomized to oral esomeprazole 20 mg b.i.d., moxifloxacin 400 mg o.d., and amoxicillin 1000 mg b.i.d. for either 7 (EMA-7) or 14 days (EMA-14). Eradication was confirmed by 13C urea breath test. Antimicrobial susceptibility testing was performed in all patients at baseline and in patients who failed treatment.RESULTS: Eighty patients were randomized, and 60% had ≥ 2 previous treatment failures. Pretreatment resistance against clarithromycin and metronidazole was found in 70.5 and 61.5% of cases, respectively. The intention-to-treat eradication rate was significantly higher after EMA-14 compared with EMA-7 (95.0 vs 78.9%, p = .036). No independent risk factor for treatment failure could be identified. There were no serious adverse events. Five of the EMA-14 patients (12.5%) compared with none of the EMA-7 patients discontinued prematurely because of adverse events (p = .031). Post-treatment resistance against moxifloxacin was found in one of seven patients with isolated organisms (14.3%).CONCLUSION: Second-line/rescue H. pylori eradication therapy with esomeprazole, moxifloxacin, and amoxicillin is very effective and well tolerated. Fourteen days of treatment significantly increase the eradication rate but also the rate of adverse events.

KW - Adult

KW - Aged

KW - Amoxicillin

KW - Anti-Bacterial Agents

KW - Anti-Ulcer Agents

KW - Aza Compounds

KW - Breath Tests

KW - Drug Therapy, Combination

KW - Esomeprazole

KW - European Continental Ancestry Group

KW - Female

KW - Fluoroquinolones

KW - Helicobacter Infections

KW - Helicobacter pylori

KW - Humans

KW - Male

KW - Microbial Sensitivity Tests

KW - Middle Aged

KW - Quinolines

KW - Salvage Therapy

KW - Time Factors

KW - Treatment Outcome

KW - Urea

KW - Journal Article

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1111/j.1523-5378.2011.00867.x

DO - 10.1111/j.1523-5378.2011.00867.x

M3 - SCORING: Journal article

C2 - 22059392

VL - 16

SP - 420

EP - 426

JO - HELICOBACTER

JF - HELICOBACTER

SN - 1083-4389

IS - 6

ER -